<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03382925</url>
  </required_header>
  <id_info>
    <org_study_id>106288</org_study_id>
    <nct_id>NCT03382925</nct_id>
  </id_info>
  <brief_title>Does Low-does Cervical Epidural Lidocaine Cause Transient Weakness?</brief_title>
  <official_title>Do Cervical Interlaminar Epidural Steroid Injections With Low-dose Lidocaine Cause Transient Objective Upper Extremity Weakness? A Prospective Randomized</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      &quot;Does low-does cervical epidural lidocaine cause transient weakness?&quot;&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cervical radicular pain is relatively common, often treated with epidural steroid injection&#xD;
      (ESI), when conservative treatments like oral analgesics, physical therapy, and activity&#xD;
      modification have failed. There are no universal clinical practice guidelines for the use of&#xD;
      diluents when CESI are performed.&#xD;
&#xD;
      Interlaminar CESI may be performed with or without the use of local anesthetics, due to&#xD;
      training bias or theoretical concerns of weakness. CESI without the benefit of local&#xD;
      anesthetic as a steroid diluent increases the latency of pain relief and may decrease&#xD;
      diagnostic information immediately after a CESI with regard to pain generators responsible&#xD;
      for symptoms, and may potentially decrease patient satisfaction.&#xD;
&#xD;
      By evaluating the effects of local anesthetic as a diluent during interlaminar cervical ESI,&#xD;
      we will enhance the safety of this treatment with regard to expectations of objective motor&#xD;
      weakness as well as post procedure pain control in the recovery phase after the injection&#xD;
      procedure.&#xD;
&#xD;
      Additionally, investigation of short-term pain, function, medication use, and global&#xD;
      impression of change following use of local anesthetic versus saline as a diluent during&#xD;
      interlaminar cervical ESI will provide evidence to inform the optimization of clinical&#xD;
      outcomes related to steroid diluent choice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not enough cervical interlaminar patients who meet criteria in order to meet recruitment goals.&#xD;
  </why_stopped>
  <start_date type="Actual">December 20, 2017</start_date>
  <completion_date type="Actual">August 19, 2020</completion_date>
  <primary_completion_date type="Actual">August 19, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Each subject will be randomized into a group assignment in a 1:1 manner, #1 or #2, as outlined in the Methods section.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Dynamometer Testing Post Procedure With Lidocaine vs Normal Saline.</measure>
    <time_frame>30 minutes post-procedure</time_frame>
    <description>Strength Testing Dynamometry post procedure with lidocaine vs normal saline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensory Exam Testing Post Procedure With Lidocaine vs Normal Saline.</measure>
    <time_frame>30 minutes post-procedure</time_frame>
    <description>Sensory Exam of upper extremity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Arterial Blood Pressure Changes</measure>
    <time_frame>30 minutes post-procedure</time_frame>
    <description>Mean Arterial Pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Changes</measure>
    <time_frame>30 minutes post-procedure</time_frame>
    <description>Heart Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity</measure>
    <time_frame>pre procedure, post-procedure, 1 day follow up, and one month follow up</time_frame>
    <description>Pain intensity will be measured by a 0-10 scale called Numerical Rating Scale. (0 being no pain and 10 being worst pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Upper Extremity Functional Index</measure>
    <time_frame>pre procedure, post-procedure, 1 day follow up, and one month follow up</time_frame>
    <description>Upper Extremity Functional Index (UEFI) Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Medication</measure>
    <time_frame>pre procedure, post-procedure, 1 day follow up, and one month follow up</time_frame>
    <description>Pain medication changes throughout treatment using MQS III calculator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change</measure>
    <time_frame>one month follow up</time_frame>
    <description>7 point question called Patient Global Impression of Change</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Cervical Radiculopathy</condition>
  <arm_group>
    <arm_group_label>cervical interlaminar with lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group #1: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL 1% lidocaine (total volume 4 mL).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cervical interlaminar with normal saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group #2: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL preservative saline (total volume 4 mL).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cervical interlaminar with lidocaine</intervention_name>
    <description>Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL 1% lidocaine.</description>
    <arm_group_label>cervical interlaminar with lidocaine</arm_group_label>
    <other_name>cervical epidural steroid injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cervical interlaminar with normal saline</intervention_name>
    <description>Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL preservative saline</description>
    <arm_group_label>cervical interlaminar with normal saline</arm_group_label>
    <other_name>cervical epidural steroid injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>2 mL lidocaine to be used as steroid diluent in group #1 cervical interlaminar procedure.</description>
    <arm_group_label>cervical interlaminar with lidocaine</arm_group_label>
    <other_name>Xylocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide</intervention_name>
    <description>2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.</description>
    <arm_group_label>cervical interlaminar with lidocaine</arm_group_label>
    <arm_group_label>cervical interlaminar with normal saline</arm_group_label>
    <other_name>Kenalog</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>2 mL of normal saline to be used as steroid diluent in group #2 cervical interlaminar procedure.</description>
    <arm_group_label>cervical interlaminar with normal saline</arm_group_label>
    <other_name>sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-80.&#xD;
&#xD;
          2. Clinical diagnosis of cervical radicular pain.&#xD;
&#xD;
          3. Magnetic resonance imaging pathology consistent with clinical symptoms/signs.&#xD;
&#xD;
          4. Numerical Rating Scale (NRS) pain score of 4 or higher.&#xD;
&#xD;
          5. Pain duration of more than 6 weeks despite trial of conservative therapy (medications,&#xD;
             physical therapy, or chiropractic care).&#xD;
&#xD;
          6. Patients who will undergo CESI for treatment of cervical radiculitis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Refusal to participate, provide consent, or provide communication and follow-up&#xD;
             information for duration of the study.&#xD;
&#xD;
          2. Inability to perform handgrip or arm strength testing.&#xD;
&#xD;
          3. Contraindications to Cervical ESI (active infection, bleeding disorders, current&#xD;
             anticoagulant or antiplatelet medication use, allergy to medications used for CIESI,&#xD;
             and pregnancy).&#xD;
&#xD;
          4. Current glucocorticoid use or ESI within past 6 months.&#xD;
&#xD;
          5. Prior cervical spine surgery.&#xD;
&#xD;
          6. Cervical spinal cord lesions; cerebrovascular, demyelinating, or other neuro-muscular&#xD;
             muscular disease.&#xD;
&#xD;
          7. Patient request for or requirement of conscious sedation for the injection procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zachary L McCormick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah Orthopaedic Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Peloso P, Gross A, Haines T, Trinh K, Goldsmith CH, Burnie S; Cervical Overview Group. Medicinal and injection therapies for mechanical neck disorders. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD000319. Review. Update in: Cochrane Database Syst Rev. 2015;5:CD000319.</citation>
    <PMID>17636629</PMID>
  </reference>
  <reference>
    <citation>Stav A, Ovadia L, Sternberg A, Kaadan M, Weksler N. Cervical epidural steroid injection for cervicobrachialgia. Acta Anaesthesiol Scand. 1993 Aug;37(6):562-6.</citation>
    <PMID>8213020</PMID>
  </reference>
  <reference>
    <citation>Ferrante FM, Wilson SP, Iacobo C, Orav EJ, Rocco AG, Lipson S. Clinical classification as a predictor of therapeutic outcome after cervical epidural steroid injection. Spine (Phila Pa 1976). 1993 May;18(6):730-6.</citation>
    <PMID>8516703</PMID>
  </reference>
  <reference>
    <citation>Botwin KP, Castellanos R, Rao S, Hanna AF, Torres-Ramos FM, Gruber RD, Bouchlas CG, Fuoco GS. Complications of fluoroscopically guided interlaminar cervical epidural injections. Arch Phys Med Rehabil. 2003 May;84(5):627-33.</citation>
    <PMID>12736872</PMID>
  </reference>
  <reference>
    <citation>Rowlingson JC, Kirschenbaum LP. Epidural analgesic techniques in the management of cervical pain. Anesth Analg. 1986 Sep;65(9):938-42.</citation>
    <PMID>3017152</PMID>
  </reference>
  <reference>
    <citation>Castagnera L, Maurette P, Pointillart V, Vital JM, Erny P, Sénégas J. Long-term results of cervical epidural steroid injection with and without morphine in chronic cervical radicular pain. Pain. 1994 Aug;58(2):239-243. doi: 10.1016/0304-3959(94)90204-6.</citation>
    <PMID>7816491</PMID>
  </reference>
  <reference>
    <citation>Lee SH, Kim KT, Kim DH, Lee BJ, Son ES, Kwack YH. Clinical outcomes of cervical radiculopathy following epidural steroid injection: a prospective study with follow-up for more than 2 years. Spine (Phila Pa 1976). 2012 May 20;37(12):1041-7. doi: 10.1097/BRS.0b013e31823b4d1f.</citation>
    <PMID>22024908</PMID>
  </reference>
  <reference>
    <citation>McCormick ZL, Nelson A, Bhave M, Zhukalin M, Kendall M, McCarthy RJ, Khan D, Nagpal G, Walega DR. A Prospective Randomized Comparative Trial of Targeted Steroid Injection Via Epidural Catheter Versus Standard C7-T1 Interlaminar Approach for the Treatment of Unilateral Cervical Radicular Pain. Reg Anesth Pain Med. 2017 Jan-Feb;42(1):82-89. doi: 10.1097/AAP.0000000000000521.</citation>
    <PMID>27922950</PMID>
  </reference>
  <reference>
    <citation>Capdevila X, Biboulet P, Rubenovitch J, Serre-Cousine O, Peray P, Deschodt J, d'Athis F. The effects of cervical epidural anesthesia with bupivacaine on pulmonary function in conscious patients. Anesth Analg. 1998 May;86(5):1033-8.</citation>
    <PMID>9585292</PMID>
  </reference>
  <reference>
    <citation>Bansal S, Turtle MJ. Inadvertent subdural spread complicating cervical epidural steroid injection with local anaesthetic agent. Anaesth Intensive Care. 2003 Oct;31(5):570-2.</citation>
    <PMID>14601282</PMID>
  </reference>
  <reference>
    <citation>Collier CB. Accidental subdural block: four more cases and a radiographic review. Anaesth Intensive Care. 1992 May;20(2):215-25. Review.</citation>
    <PMID>1317680</PMID>
  </reference>
  <reference>
    <citation>Plastaras C, McCormick ZL, Garvan C, Macron D, Joshi A, Chimes G, Smeal W, Rittenberg J, Kennedy DJ. Adverse events associated with fluoroscopically guided lumbosacral transforaminal epidural steroid injections. Spine J. 2015 Oct 1;15(10):2157-65. doi: 10.1016/j.spinee.2015.05.034. Epub 2015 Jun 9.</citation>
    <PMID>26065819</PMID>
  </reference>
  <reference>
    <citation>Ortiz MP, Godoy MC, Schlosser RS, Ortiz RP, Godoy JP, Santiago ES, Rigo FK, Beck V, Duarte T, Duarte MM, Menezes MS. Effect of endovenous lidocaine on analgesia and serum cytokines: double-blinded and randomized trial. J Clin Anesth. 2016 Dec;35:70-77. doi: 10.1016/j.jclinane.2016.07.021. Epub 2016 Aug 6.</citation>
    <PMID>27871598</PMID>
  </reference>
  <reference>
    <citation>Gray A, Marrero-Berrios I, Weinberg J, Manchikalapati D, SchianodiCola J, Schloss RS, Yarmush J. The effect of local anesthetic on pro-inflammatory macrophage modulation by mesenchymal stromal cells. Int Immunopharmacol. 2016 Apr;33:48-54. doi: 10.1016/j.intimp.2016.01.019. Epub 2016 Feb 6.</citation>
    <PMID>26854576</PMID>
  </reference>
  <reference>
    <citation>van der Wal SE, van den Heuvel SA, Radema SA, van Berkum BF, Vaneker M, Steegers MA, Scheffer GJ, Vissers KC. The in vitro mechanisms and in vivo efficacy of intravenous lidocaine on the neuroinflammatory response in acute and chronic pain. Eur J Pain. 2016 May;20(5):655-74. doi: 10.1002/ejp.794. Epub 2015 Dec 18. Review.</citation>
    <PMID>26684648</PMID>
  </reference>
  <reference>
    <citation>Bohannon RW. Reference values for extremity muscle strength obtained by hand-held dynamometry from adults aged 20 to 79 years. Arch Phys Med Rehabil. 1997 Jan;78(1):26-32.</citation>
    <PMID>9014953</PMID>
  </reference>
  <reference>
    <citation>Bohannon RW. Grip strength impairments among older adults receiving physical therapy in a home-care setting. Percept Mot Skills. 2010 Dec;111(3):761-4.</citation>
    <PMID>21319615</PMID>
  </reference>
  <reference>
    <citation>Hayes K, Walton JR, Szomor ZL, Murrell GA. Reliability of 3 methods for assessing shoulder strength. J Shoulder Elbow Surg. 2002 Jan-Feb;11(1):33-9.</citation>
    <PMID>11845146</PMID>
  </reference>
  <reference>
    <citation>Kolber MJ, Beekhuizen K, Cheng MS, Fiebert IM. The reliability of hand-held dynamometry in measuring isometric strength of the shoulder internal and external rotator musculature using a stabilization device. Physiother Theory Pract. 2007 Mar-Apr;23(2):119-24.</citation>
    <PMID>17530541</PMID>
  </reference>
  <reference>
    <citation>Awatani T, Mori S, Shinohara J, Koshiba H, Nariai M, Tatsumi Y, Nagata A, Morikita I. Same-session and between-day intra-rater reliability of hand-held dynamometer measurements of isometric shoulder extensor strength. J Phys Ther Sci. 2016 Mar;28(3):936-9. doi: 10.1589/jpts.28.936. Epub 2016 Mar 31.</citation>
    <PMID>27134388</PMID>
  </reference>
  <reference>
    <citation>Fieseler G, Molitor T, Irlenbusch L, Delank KS, Laudner KG, Hermassi S, Schwesig R. Intrarater reliability of goniometry and hand-held dynamometry for shoulder and elbow examinations in female team handball athletes and asymptomatic volunteers. Arch Orthop Trauma Surg. 2015 Dec;135(12):1719-26. doi: 10.1007/s00402-015-2331-6. Epub 2015 Sep 19.</citation>
    <PMID>26386839</PMID>
  </reference>
  <reference>
    <citation>Kirshblum SC, Waring W, Biering-Sorensen F, Burns SP, Johansen M, Schmidt-Read M, Donovan W, Graves D, Jha A, Jones L, Mulcahey MJ, Krassioukov A. Reference for the 2011 revision of the International Standards for Neurological Classification of Spinal Cord Injury. J Spinal Cord Med. 2011 Nov;34(6):547-54. doi: 10.1179/107902611X13186000420242.</citation>
    <PMID>22330109</PMID>
  </reference>
  <reference>
    <citation>Kim JK, Park MG, Shin SJ. What is the minimum clinically important difference in grip strength? Clin Orthop Relat Res. 2014 Aug;472(8):2536-41. doi: 10.1007/s11999-014-3666-y. Epub 2014 May 10.</citation>
    <PMID>24817380</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 4, 2017</study_first_submitted>
  <study_first_submitted_qc>December 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <results_first_submitted>August 19, 2020</results_first_submitted>
  <results_first_submitted_qc>April 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2021</results_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Zack McCormick</investigator_full_name>
    <investigator_title>Zachary L. McCormick, MD</investigator_title>
  </responsible_party>
  <keyword>cervical epidural steroid injection</keyword>
  <keyword>local anesthetic</keyword>
  <keyword>upper extremity weakness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radiculopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT03382925/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cervical Interlaminar With Lidocaine</title>
          <description>Group #1: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL 1% lidocaine (total volume 4 mL).&#xD;
cervical interlaminar with lidocaine: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL 1% lidocaine.&#xD;
Lidocaine: 2 mL lidocaine to be used as steroid diluent in group #1 cervical interlaminar procedure.&#xD;
Triamcinolone Acetonide: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.</description>
        </group>
        <group group_id="P2">
          <title>Cervical Interlaminar With Normal Saline</title>
          <description>Group #2: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL preservative saline (total volume 4 mL).&#xD;
cervical interlaminar with normal saline: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL preservative saline&#xD;
Triamcinolone Acetonide: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.&#xD;
Normal saline: 2 mL of normal saline to be used as steroid diluent in group #2 cervical interlaminar procedure.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cervical Interlaminar With Lidocaine</title>
          <description>Group #1: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL 1% lidocaine (total volume 4 mL).&#xD;
cervical interlaminar with lidocaine: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL 1% lidocaine.&#xD;
Lidocaine: 2 mL lidocaine to be used as steroid diluent in group #1 cervical interlaminar procedure.&#xD;
Triamcinolone Acetonide: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.</description>
        </group>
        <group group_id="B2">
          <title>Cervical Interlaminar With Normal Saline</title>
          <description>Group #2: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL preservative saline (total volume 4 mL).&#xD;
cervical interlaminar with normal saline: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL preservative saline&#xD;
Triamcinolone Acetonide: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.&#xD;
Normal saline: 2 mL of normal saline to be used as steroid diluent in group #2 cervical interlaminar procedure.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Dynamometer Testing Post Procedure With Lidocaine vs Normal Saline.</title>
        <description>Strength Testing Dynamometry post procedure with lidocaine vs normal saline.</description>
        <time_frame>30 minutes post-procedure</time_frame>
        <population>Data was not collected. Study terminated early due to low enrollment. Zero participants completed both arms requirements. No statistical analysis obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervical Interlaminar With Lidocaine</title>
            <description>Group #1: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL 1% lidocaine (total volume 4 mL).&#xD;
cervical interlaminar with lidocaine: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL 1% lidocaine.&#xD;
Lidocaine: 2 mL lidocaine to be used as steroid diluent in group #1 cervical interlaminar procedure.&#xD;
Triamcinolone Acetonide: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.</description>
          </group>
          <group group_id="O2">
            <title>Cervical Interlaminar With Normal Saline</title>
            <description>Group #2: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL preservative saline (total volume 4 mL).&#xD;
cervical interlaminar with normal saline: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL preservative saline&#xD;
Triamcinolone Acetonide: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.&#xD;
Normal saline: 2 mL of normal saline to be used as steroid diluent in group #2 cervical interlaminar procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Dynamometer Testing Post Procedure With Lidocaine vs Normal Saline.</title>
          <description>Strength Testing Dynamometry post procedure with lidocaine vs normal saline.</description>
          <population>Data was not collected. Study terminated early due to low enrollment. Zero participants completed both arms requirements. No statistical analysis obtained.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sensory Exam Testing Post Procedure With Lidocaine vs Normal Saline.</title>
        <description>Sensory Exam of upper extremity</description>
        <time_frame>30 minutes post-procedure</time_frame>
        <population>Data was not collected. Study terminated early due to low enrollment. Zero participants completed both arms requirements. No statistical analysis obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervical Interlaminar With Lidocaine</title>
            <description>Group #1: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL 1% lidocaine (total volume 4 mL).&#xD;
cervical interlaminar with lidocaine: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL 1% lidocaine.&#xD;
Lidocaine: 2 mL lidocaine to be used as steroid diluent in group #1 cervical interlaminar procedure.&#xD;
Triamcinolone Acetonide: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.</description>
          </group>
          <group group_id="O2">
            <title>Cervical Interlaminar With Normal Saline</title>
            <description>Group #2: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL preservative saline (total volume 4 mL).&#xD;
cervical interlaminar with normal saline: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL preservative saline&#xD;
Triamcinolone Acetonide: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.&#xD;
Normal saline: 2 mL of normal saline to be used as steroid diluent in group #2 cervical interlaminar procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Sensory Exam Testing Post Procedure With Lidocaine vs Normal Saline.</title>
          <description>Sensory Exam of upper extremity</description>
          <population>Data was not collected. Study terminated early due to low enrollment. Zero participants completed both arms requirements. No statistical analysis obtained.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Arterial Blood Pressure Changes</title>
        <description>Mean Arterial Pressure</description>
        <time_frame>30 minutes post-procedure</time_frame>
        <population>Data was not collected. Study terminated early due to low enrollment. Zero participants completed both arms requirements. No statistical analysis obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervical Interlaminar With Lidocaine</title>
            <description>Group #1: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL 1% lidocaine (total volume 4 mL).&#xD;
cervical interlaminar with lidocaine: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL 1% lidocaine.&#xD;
Lidocaine: 2 mL lidocaine to be used as steroid diluent in group #1 cervical interlaminar procedure.&#xD;
Triamcinolone Acetonide: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.</description>
          </group>
          <group group_id="O2">
            <title>Cervical Interlaminar With Normal Saline</title>
            <description>Group #2: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL preservative saline (total volume 4 mL).&#xD;
cervical interlaminar with normal saline: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL preservative saline&#xD;
Triamcinolone Acetonide: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.&#xD;
Normal saline: 2 mL of normal saline to be used as steroid diluent in group #2 cervical interlaminar procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Arterial Blood Pressure Changes</title>
          <description>Mean Arterial Pressure</description>
          <population>Data was not collected. Study terminated early due to low enrollment. Zero participants completed both arms requirements. No statistical analysis obtained.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate Changes</title>
        <description>Heart Rate</description>
        <time_frame>30 minutes post-procedure</time_frame>
        <population>Data was not collected. Study terminated early due to low enrollment. Zero participants completed both arms requirements. No statistical analysis obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervical Interlaminar With Lidocaine</title>
            <description>Group #1: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL 1% lidocaine (total volume 4 mL).&#xD;
cervical interlaminar with lidocaine: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL 1% lidocaine.&#xD;
Lidocaine: 2 mL lidocaine to be used as steroid diluent in group #1 cervical interlaminar procedure.&#xD;
Triamcinolone Acetonide: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.</description>
          </group>
          <group group_id="O2">
            <title>Cervical Interlaminar With Normal Saline</title>
            <description>Group #2: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL preservative saline (total volume 4 mL).&#xD;
cervical interlaminar with normal saline: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL preservative saline&#xD;
Triamcinolone Acetonide: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.&#xD;
Normal saline: 2 mL of normal saline to be used as steroid diluent in group #2 cervical interlaminar procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate Changes</title>
          <description>Heart Rate</description>
          <population>Data was not collected. Study terminated early due to low enrollment. Zero participants completed both arms requirements. No statistical analysis obtained.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity</title>
        <description>Pain intensity will be measured by a 0-10 scale called Numerical Rating Scale. (0 being no pain and 10 being worst pain)</description>
        <time_frame>pre procedure, post-procedure, 1 day follow up, and one month follow up</time_frame>
        <population>Data was not collected. Study terminated early due to low enrollment. Zero participants completed both arms requirements. No statistical analysis obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervical Interlaminar With Lidocaine</title>
            <description>Group #1: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL 1% lidocaine (total volume 4 mL).&#xD;
cervical interlaminar with lidocaine: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL 1% lidocaine.&#xD;
Lidocaine: 2 mL lidocaine to be used as steroid diluent in group #1 cervical interlaminar procedure.&#xD;
Triamcinolone Acetonide: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.</description>
          </group>
          <group group_id="O2">
            <title>Cervical Interlaminar With Normal Saline</title>
            <description>Group #2: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL preservative saline (total volume 4 mL).&#xD;
cervical interlaminar with normal saline: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL preservative saline&#xD;
Triamcinolone Acetonide: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.&#xD;
Normal saline: 2 mL of normal saline to be used as steroid diluent in group #2 cervical interlaminar procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity</title>
          <description>Pain intensity will be measured by a 0-10 scale called Numerical Rating Scale. (0 being no pain and 10 being worst pain)</description>
          <population>Data was not collected. Study terminated early due to low enrollment. Zero participants completed both arms requirements. No statistical analysis obtained.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Upper Extremity Functional Index</title>
        <description>Upper Extremity Functional Index (UEFI) Questionnaire</description>
        <time_frame>pre procedure, post-procedure, 1 day follow up, and one month follow up</time_frame>
        <population>Data was not collected. Study terminated early due to low enrollment. Zero participants completed both arms requirements. No statistical analysis obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervical Interlaminar With Lidocaine</title>
            <description>Group #1: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL 1% lidocaine (total volume 4 mL).&#xD;
cervical interlaminar with lidocaine: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL 1% lidocaine.&#xD;
Lidocaine: 2 mL lidocaine to be used as steroid diluent in group #1 cervical interlaminar procedure.&#xD;
Triamcinolone Acetonide: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.</description>
          </group>
          <group group_id="O2">
            <title>Cervical Interlaminar With Normal Saline</title>
            <description>Group #2: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL preservative saline (total volume 4 mL).&#xD;
cervical interlaminar with normal saline: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL preservative saline&#xD;
Triamcinolone Acetonide: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.&#xD;
Normal saline: 2 mL of normal saline to be used as steroid diluent in group #2 cervical interlaminar procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Upper Extremity Functional Index</title>
          <description>Upper Extremity Functional Index (UEFI) Questionnaire</description>
          <population>Data was not collected. Study terminated early due to low enrollment. Zero participants completed both arms requirements. No statistical analysis obtained.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Medication</title>
        <description>Pain medication changes throughout treatment using MQS III calculator</description>
        <time_frame>pre procedure, post-procedure, 1 day follow up, and one month follow up</time_frame>
        <population>Data was not collected. Study terminated early due to low enrollment. Zero participants completed both arms requirements. No statistical analysis obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervical Interlaminar With Lidocaine</title>
            <description>Group #1: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL 1% lidocaine (total volume 4 mL).&#xD;
cervical interlaminar with lidocaine: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL 1% lidocaine.&#xD;
Lidocaine: 2 mL lidocaine to be used as steroid diluent in group #1 cervical interlaminar procedure.&#xD;
Triamcinolone Acetonide: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.</description>
          </group>
          <group group_id="O2">
            <title>Cervical Interlaminar With Normal Saline</title>
            <description>Group #2: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL preservative saline (total volume 4 mL).&#xD;
cervical interlaminar with normal saline: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL preservative saline&#xD;
Triamcinolone Acetonide: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.&#xD;
Normal saline: 2 mL of normal saline to be used as steroid diluent in group #2 cervical interlaminar procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Medication</title>
          <description>Pain medication changes throughout treatment using MQS III calculator</description>
          <population>Data was not collected. Study terminated early due to low enrollment. Zero participants completed both arms requirements. No statistical analysis obtained.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Change</title>
        <description>7 point question called Patient Global Impression of Change</description>
        <time_frame>one month follow up</time_frame>
        <population>Data was not collected. Study terminated early due to low enrollment. Zero participants completed both arms requirements. No statistical analysis obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervical Interlaminar With Lidocaine</title>
            <description>Group #1: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL 1% lidocaine (total volume 4 mL).&#xD;
cervical interlaminar with lidocaine: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL 1% lidocaine.&#xD;
Lidocaine: 2 mL lidocaine to be used as steroid diluent in group #1 cervical interlaminar procedure.&#xD;
Triamcinolone Acetonide: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.</description>
          </group>
          <group group_id="O2">
            <title>Cervical Interlaminar With Normal Saline</title>
            <description>Group #2: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL preservative saline (total volume 4 mL).&#xD;
cervical interlaminar with normal saline: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL preservative saline&#xD;
Triamcinolone Acetonide: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.&#xD;
Normal saline: 2 mL of normal saline to be used as steroid diluent in group #2 cervical interlaminar procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Change</title>
          <description>7 point question called Patient Global Impression of Change</description>
          <population>Data was not collected. Study terminated early due to low enrollment. Zero participants completed both arms requirements. No statistical analysis obtained.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected on each participant from their first day of enrollment until one month post procedure (Timeframe was approximately 1 1/2 months for each participant from enrollment, strength testing/procedure, to one month follow up). Duration of study enrollment was from December 20, 2017 to August 19, 2020 when study enrollment was closed.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cervical Interlaminar With Lidocaine</title>
          <description>Group #1: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL 1% lidocaine (total volume 4 mL).&#xD;
cervical interlaminar with lidocaine: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL 1% lidocaine.&#xD;
Lidocaine: 2 mL lidocaine to be used as steroid diluent in group #1 cervical interlaminar procedure.&#xD;
Triamcinolone Acetonide: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.</description>
        </group>
        <group group_id="E2">
          <title>Cervical Interlaminar With Normal Saline</title>
          <description>Group #2: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL preservative saline (total volume 4 mL).&#xD;
cervical interlaminar with normal saline: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL preservative saline&#xD;
Triamcinolone Acetonide: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.&#xD;
Normal saline: 2 mL of normal saline to be used as steroid diluent in group #2 cervical interlaminar procedure.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Procedure AE</sub_title>
                <description>AE for cardiac and unrelated to procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to low enrollment which ended up being the greatest limitation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Shellie Cunnungham</name_or_title>
      <organization>University of Utah, Department of Physical Medicine and Rehabilitation</organization>
      <phone>801-587-5488</phone>
      <email>shellie.cunningham@hsc.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

